Molecular profiling and tumor boards face gaps in biliary tract cancer care

The Structural Gap in Modern Liver Cancer Care

The traditional tumor board model, long considered the gold standard for multidisciplinary cancer care, is facing a modern reckoning. As precision medicine shifts the focus toward actionable molecular mutations, the gap between a high-level recommendation and actual patient treatment has become a critical point of failure. According to a report published in International Journal of Clinical Oncology, identifying mutations like FGFR2 fusions or IDH1 in biliary tract cancers (BTC) is now a medical imperative, yet the transition from diagnosis to targeted therapy remains fraught with logistical hurdles.

For many health systems, the challenge is no longer just identifying the right drug—it is managing the high-friction process of prior authorizations and cross-specialty coordination. While a board might recommend a sophisticated, targeted therapy, the patient often remains in a state of limbo if no single person owns the responsibility of navigating the administrative requirements.

Molecular Profiling as a Mandatory Benchmark

The integration of molecular testing is no longer an optional component of the first discussion; it is a prerequisite for precision care. At institutions where this is prioritized, the workflow is streamlined through mandatory profiling at the point of biopsy or surgical resection. By utilizing a single vendor for these tests, hospitals can remove the variability that often plagues diagnostic results.

Ownership of these results generally rests with the primary treating physician—typically a hepatobiliary surgeon, medical oncologist, or hepatologist. These specialists bring the data to the tumor board, where the focus shifts to first-line therapy or, in the event of progression, to targeting specific alterations. However, the efficacy of this process depends entirely on the board’s ability to act on the findings.

The Hub-and-Spoke Model vs. Virtual Alternatives

For patients treated in community settings without access to an on-site specialized tumor board, the hub-and-spoke model offers a path to higher-quality care. In this structure, a centralized board at a major health system reviews cases from smaller, outlying hospitals via virtual connection. This model has been in use since 2009, providing a resource-efficient way to extend expertise.

Yet, this system is not without its flaws. There is rarely a mandate forcing local physicians to present every patient case, meaning a significant number of patients may never benefit from the board’s collective expertise. Virtual tumor boards—those not affiliated with the patient’s institution—have attempted to bridge this gap, but they have largely struggled to gain traction. The logistical complexities, combined with the stringent requirements of the Health Insurance Portability and Accountability Act (HIPAA), have rendered the truly independent virtual tumor board an elusive solution.

Closing the Implementation Gap

The most frequent point of failure in the cancer care continuum is not the decision-making process itself, but the implementation of the plan. Because tumor board recommendations are nonbinding, the burden of execution falls back on the treating physician.

“Unless a navigator is present and takes ownership of the plan, including scheduling the patient with various providers and scheduling any additional procedures, such as additional chest or abdominal imaging or a PET scan, these steps might fall through the cracks,” the report notes.

This is where the tumor board navigator becomes essential. Without a dedicated advocate to ensure that insurance authorizations are secured and appointments are synchronized, even the most sound clinical plan can result in delayed or incomplete care. The difference between a successful outcome and a stalled one often comes down to this specific role.

Measuring Success Beyond Survival Rates

Determining whether a tumor board is actually improving patient outcomes requires a shift in how success is measured. While NCI-designated comprehensive cancer centers focus on benchmarks like staging adequacy and survivorship programs, there is a clear need to measure the human element. The industry is currently struggling to quantify intangibles—such as quality of life, symptom management, and mental health—which are significantly harder to track than overall survival or disease control rates.

As the industry looks toward the next three to five years, artificial intelligence is poised to play a larger role. While algorithmic approaches are already appearing in other fields like lung cancer, hepatobiliary disease remains a more complex landscape defined by local expertise and nuanced decision-making. The integration of AI will likely be incremental, serving as a tool to support, rather than replace, the human-led tumor board. For now, the most significant improvements in patient care will likely come from solving the logistical bottlenecks that continue to separate the recommendation from the treatment.